Sailong Pharmaceutical Group (002898) Fair Value & Analysis
Healthcare · CN · Market cap 65.1M CNY
Fair value as of: Aug 7, 2026
From 2 valuation models · updated 3 days ago
Fair value updated Aug 7, 2026, revised from ¥0.1100 to ¥0.5193 (+372.1%) since Jul 22, 2026. Share price −95.5% over the past month.
Below-average quality, screening 40% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (¥0.3790). The market is more pessimistic than our downside scenario.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 7, 2026.
How to read this chart
60‑month range ¥0.3200 – ¥18.58 · fair‑value band ¥0.3790 – ¥0.6575 · the ¥0.3700 price screens below the ¥0.5193 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 7, 2026.
Analysis
Sailong Pharmaceutical Group (002898) currently trades at ¥0.3700, while our model-based Fair Value estimate is ¥0.5193, implying the stock looks roughly 40.4% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Sailong Pharmaceutical Group generated revenue of 618M CNY at a net margin of -20.9%. Revenue grew 183.8% year over year. It earns a return on equity of -29.1%. Net debt stands at 31.9M CNY. Fundamentals as of Aug 7, 2026
Our scenario range runs from ¥0.3790 (bear case) to ¥0.6575 (bull case); at ¥0.3700, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 40%, 002898 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 2 models by family
Widest divergence: Multiples (¥2.96) versus Asset-Based (¥1.45). Highest evidence: EV/EBITDA (54).
Notify me when 002898 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China.
Full company description
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pantoprazole sodium products, etc. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding drugs, analgesics, and other fields. Sailong Pharmaceutical Group Co.,Ltd. was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co.,Ltd. in September 2021. The company was founded in 2002 and is based in Zhuhai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sailong Pharmaceutical Group reported revenue of ¥519M in FY2025 versus ¥247M in FY2021, a compound +20.4%/yr. Reported net income was −¥121M in FY2025.
Watch 002898: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Sailong Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sailong Pharmaceutical Group (002898) overvalued or undervalued?
What is the fair value of 002898?
What is the quality score of 002898?
What is the revenue of Sailong Pharmaceutical Group (002898)?
What is the net profit margin of 002898?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sailong Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.